Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet-Reference-Cited by-同舟云学术

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet

Published:2020-09-29 Issue:3 Volume:109 Page:746-753
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Gueneau de Mussy Pierre¹,Sidharta Patricia N.²,Wuerzner Gregoire¹,Maillard Marc P.¹,Guérard Nicolas²,Iglarz Marc³,Flamion Bruno⁴,Dingemanse Jasper²,Burnier Michel¹

Affiliation:

1. Service of Nephrology and Hypertension Department of Medicine University Hospital Lausanne Switzerland

2. Department of Clinical Pharmacology Idorsia Pharmaceuticals Ltd. Allschwil Switzerland

3. Department of Pharmacology Idorsia Pharmaceuticals Ltd. Allschwil Switzerland

4. Department of Strategic Development Idorsia Pharmaceuticals Ltd. Allschwil Switzerland

Funder

Centre Hospitalier Universitaire Vaudois

Actelion Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2043

Reference32 articles.

1. Endothelin

2. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin

3. Therapeutic potential of endothelin receptor antagonism in kidney disease

4. Endothelin receptors, renal effects and blood pressure

5. Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging therapies targeting cardiovascular risk factors to prevent or delay the onset of heart failure;American Journal of Pharmacotherapy and Pharmaceutical Sciences;2024-07-09

2. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension;Journal of Pharmacokinetics and Pharmacodynamics;2024-02-08

3. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential;Drug Discovery Today;2023-11

4. Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation;British Journal of Pharmacology;2023-10-21

5. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis;Current Problems in Cardiology;2023-07